Your browser is no longer supported. Please, upgrade your browser.
Settings
PHIO Phio Pharmaceuticals Corp. daily Stock Chart
PHIO [NASD]
Phio Pharmaceuticals Corp.
Index- P/E- EPS (ttm)-0.63 Insider Own4.80% Shs Outstand27.44M Perf Week-7.01%
Market Cap5.90M Forward P/E- EPS next Y-0.35 Insider Trans- Shs Float24.82M Perf Month-33.65%
Income-7.40M PEG- EPS next Q-0.08 Inst Own8.90% Short Float0.70% Perf Quarter-43.48%
Sales0.08M P/S75.64 EPS this Y81.10% Inst Trans0.37% Short Ratio1.26 Perf Half Y-51.36%
Book/sh0.40 P/B0.54 EPS next Y2.80% ROA-65.70% Target Price2.00 Perf Year-57.93%
Cash/sh0.39 P/C0.55 EPS next 5Y- ROE-80.40% 52W Range0.20 - 0.53 Perf YTD-34.83%
Dividend- P/FCF- EPS past 5Y67.50% ROI-54.10% 52W High-59.43% Beta1.65
Dividend %- Quick Ratio5.90 Sales past 5Y-19.10% Gross Margin- 52W Low7.50% ATR0.03
Employees9 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)31.92 Volatility17.73% 12.74%
OptionableNo Debt/Eq0.00 EPS Q/Q81.90% Profit Margin- Rel Volume1.30 Prev Close0.23
ShortableYes LT Debt/Eq0.00 EarningsAug 13 Payout- Avg Volume137.19K Price0.22
Recom- SMA20-23.87% SMA50-32.73% SMA200-43.89% Volume177,978 Change-6.52%
Oct-11-19 08:00AM  Phio Pharmaceuticals Announces Adjournment of 2019 Annual Meeting of Stockholders PR Newswire -6.52%
Sep-09-19 07:10AM  Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy PR Newswire -9.25%
Sep-03-19 07:10AM  Phio Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Healthcare Conference PR Newswire
Aug-26-19 11:30AM  PHIO: Overcoming Immune Checkpoints Zacks Small Cap Research
Aug-15-19 07:05AM  Phio Pharmaceuticals and Helmholtz Zentrum München to Collaborate on Novel Targets for the Use of Self-Delivering RNAi In T Cell and NK Cell Adoptive Cell Therapy Therapeutics PR Newswire
Aug-12-19 05:10PM  Phio Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Jun-12-19 10:30AM  PHIO: Two Compounds Entering Clinic in 2020 Zacks Small Cap Research
May-20-19 07:05AM  Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum PR Newswire
May-14-19 05:15PM  Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights PR Newswire +6.35%
Apr-22-19 10:15AM  PHIO: Activation in the Tumor Microenvironment Zacks Small Cap Research
Apr-12-19 09:32AM  After name change, Phio Pharma 'reinvents' gene-silencing pipeline American City Business Journals
Apr-10-19 07:05AM  Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer PR Newswire
Mar-28-19 07:05AM  Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment PR Newswire
Mar-27-19 05:20PM  Phio Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights PR Newswire
Mar-25-19 07:05AM  Phio Pharmaceuticals to Present Poster on the Use of Self-Delivering RNAi in Immuno-oncology at the AACR Annual Meeting 2019 PR Newswire +7.17%
Feb-15-19 07:15AM  Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 PR Newswire
Dec-18-18 07:05AM  Phio Pharmaceuticals to Present at Biotech Showcase 2019 in San Francisco PR Newswire
Dec-04-18 07:05AM  Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 PR Newswire
Dec-03-18 11:30AM  PHIO: Soldiering On as We Wait for Bids Zacks Small Cap Research
Nov-19-18 07:00AM  RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. PR Newswire
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum Munchen. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.